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ABSTRACT
Tumor-stimulated bone resorption fuels tumor growth and marks a dramatic decline in the health and prognosis of breast cancer
patients. Identifying mechanisms that mediate cross-talk between tumor and bone remains a key challenge. We previously demon-
strated that breast cancer cells expressing high levels of heparanase exhibit enhanced shedding of the syndecan-1 proteoglycan.
Moreover, when these heparanase-high cells are implanted in the mammary fat pad, they elevate bone resorption. In this study,
conditioned medium from breast cancer cells expressing high levels of heparanase was shown to significantly stimulate human
osteoclastogenesis in vitro (p<.05). The osteoclastogenic activity in the medium of heparanase-high cells was traced to the presence of
syndecan-1, intact heparan sulfate chains, and heat-labile factor(s), including the chemokine interleukin 8 (IL-8). The enhanced
osteoclastogenesis promoted by the heparanase-high cells results in a dramatic increase in bone resorption in vitro. In addition,
the long bones of animals bearing heparanase-high tumors in the mammary fat pad had significantly higher numbers of osteoclasts
comparedwith animalsbearingtumors expressing low levelsofheparanase (p<.05). Together thesedata suggest thatsyndecan-1 shed
by tumor cells exerts biologic effects distal to the primary tumor and that it participates in driving osteoclastogenesis and the resulting
bone destruction.  2010 American Society for Bone and Mineral Research.
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Introduction
B
one metastasis is a frequent, often debilitating, and painful
complication of breast cancer,
(1) yet the mechanisms by
which breast cancer cells colonize bone to form metastases
remainpoorly understood.Anumberofmoleculeselaboratedby
breast cancer cells, including parathyroid hormone–related
peptide (PTHrP),
(2) interleukin 8 (IL-8),
(3) IL-11,
(4) and many
others, have been shown to stimulate osteoclastogenesis and
the resulting bone destruction.
(5)
Once osteoclasts are activated to resorb bone, growth factors
that are bound to the bone matrix and that can stimulate
metastatic tumor cell growth are released.
(6) This positive-
feedback loop produces a microenvironment within the bone
marrow that has the potential to sustain tumor growth.
(5) The
cross-talk between the breast cancer cells colonizing bone and
the resident osteoclasts (and their precursors) is believed to be
particularly important for the initial establishment of bone
metastases, at least in animal models.
(6) For example, in various
mouse models, treatment with bone-resorption-inhibiting
bisphosphonates reduces the number of bone metastatic foci
if administered prior to the arrival of the tumor cells in bone.
(7)
However, bisphosphonates do not inhibit the growth of
metastatic foci once they are established in bone.
(7) Thus,
although bisphosphonates maintain bone density in breast
cancer patients with bone metastases and have been shown to
increase disease-free survival in premenopausal patients with
estrogen-responsive early breast cancer,
(8) in animal models,
bisphosphonates do not slow the growth of established lesions.
This suggests that after becoming established, bone metastases
may no longer require active bone resorption.
(7) The question of
how osteoclastogenesis and bone resorption are stimulated
initially by tumor cells prior to and after their arrival in the
skeleton remains largely unanswered.
Heparanase is an enzyme that acts both at the cell surface and
within the extracellular matrix to degrade polymeric heparan
sulfate chains into shorter-chain-length, biologically active
oligosaccharides of 18 to 20 sugar residues.
(9) In human breast
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1295cancer, heparanase overexpression has been associated with
increased metastasis and poor prognosis.
(10) Heparanase may
contribute to disease progression through its well-established
proangiogenic effects that drive vessel formation and fuel
explosive tumor growth.
(11–14) In addition to stimulating tumor
growth,
(11,12,15–17) heparanase has been implicated in local
invasion and metastasis
(18,19) and is upregulated by estrogen.
(20)
One of the major heparan sulfates expressed on the surface of
human breast cancer cell lines and human breast tumors is
syndecan-1.
(21,22) Syndecan-1 is a transmembrane (type I)
heparan sulfate proteoglycan known to regulate multiple
biologic functions, including cell–extracellular matrix adhesion,
and it has a well-documented and important role as a growth
factor coreceptor.
(23) In addition, syndecan-1 on the surfaces of
cellscanactivatecell-surfaceintegrins,therebypromotingbreast
tumor cell spread, migration, and angiogenesis.
(24,25) In breast
cancerpatients,syndecan-1isupregulatedinthereactivestroma
adjacent to malignant tumor cells
(26) and is highly abundant in
the bone marrow stroma of patients with multiple myeloma.
(27)
In fact, the shedding of syndecan-1 from cells within primary
human breast tumors has emerged as an important regulator of
the tumor microenvironment, where syndecan-1 is associated
with enhanced tumor proliferation, angiogenesis, and the
activity of matrix metalloproteinases (MMPs).
(28) When shed
from the cell surface, syndecan-1 can facilitate the growth,
angiogenesis, and metastasis of tumors.
(29,30) Importantly, the
functional activities of syndecan-1 can be modulated by the
enzymatic activity of heparanase, which specifically cleaves
heparan sulfate chains.
(31)
Previously we demonstrated that bone resorption occurs
before the appearance of overt bony metastases in animals
bearing breast tumors overexpressing heparanase.
(12) Subse-
quently, we also demonstrated that breast cancer cells over-
expressingheparanasereleaseelevatedlevelsofsyndecan-1into
the growth medium
(29) and, moreover, that the overexpression
of catalytically inactive heparanase did not increase the
shedding of syndecan-1.
(29) These data suggest that factors
may be released into the systemic circulation by breast cancer
cells overexpressing heparanase that may stimulate distant
osteoclastogenesis and the subsequent bone destruction.
(12) In
the studies described here, increased osteoclast numbers and
bone resorption were observed in the long bones of animals
bearing human breast tumor mammary fat pad xenografts
overexpressing active heparanase. In addition, in vitro osteo-
clastogenesis assays demonstrated that shed syndecan-1 was
required for the enhanced osteoclastogenic activity of the tumor
cells. These findings identify syndecan-1 that is shed by tumor
cells expressing heparanase as a potent pro-osteoclastogenic
agent.
Materials and Methods
Cell culture
The MDA MET-derived cell lines HPSE-Low, HPSE-High, M225,
and M343 were maintained in DMEM supplemented with 10%
fetal bovine serum (FBS) at 378C in sterile culture dishes as
described previously.
(12,29,32) All cell lines were Mycoplasma-free.
Cells were subcultured by trypsinization in 0.5% trypsin (Sigma,
St. Louis, MO) and 0.5mM EDTA in Hank’s balanced salt solution
(HBSS) without calcium or magnesium in a laminar flow hood
during their logarithmic phase of growth. For human osteoclas-
togenesis assays, 48-hour conditioned media (containing serum)
from HPSE-High, HPSE-Low, M225, and M343 cells were
collected, diluted 50% in a modified essential medium (a-
MEM) and added to cultures of human peripheral blood
mononuclear cells (as described below). We have shown
previously that the 50% dilution of MDA MET-conditioned
medium contains pro-osteoclastogenic activity, whereas 100%
conditioned medium contains inhibitors that induce osteoclast
progenitor death.
(33)
Heparanase activity assay
The heparanase activity assay used an immobilized [
3H]heparan
sulfate substrate and was performed as described pre-
viously.
(11,34) Purified recombinant heparanase (46ng; gener-
ouslyprovidedbyDrHuaQuanMiao,ImCloneInc.,NewYork,NY)
was used as the positive control, and buffer was used as the
negative control. Each sample was normalized to equal volume
and tested in triplicate on at least two separate occasions.
IL-8 ELISA
The production and secretion of IL-8 was measured in
conditioned medium using a commercially available enzyme-
linked immunosorbent assay (ELISA) kit (R&D Systems, Minnea-
polis, MN, USA) according to the manufacturer’s instructions. The
commercially available IL-8 ELISA specifically detects human IL-8.
IL-8 concentrations in conditioned media were calculated from a
standard curve generated by adding recombinant IL-8 to the
specific unconditioned medium and were considered undetect-
able if media concentrations were less than 0.3pmol/L before
correction for cell number. Murine NIH 3T3 cells tested with the
IL-8 kit did not secrete IL-8 cross-reacting products. To block IL-8
activity, an IL-8 antibody (a kind gift of Dr Rakesh Singh,
University of Nebraska, Omaha, NE, USA) was used as described
previously.
(32) Briefly, 200 mg/ml of IL-8 antibody was added
every other day to osteoclast cultures. All IL-8 biologic activity is
inhibited by this treatment.
(33)
Western blots
Cells were extracted, and Western blot analysis was performed
using 60mg of protein per lane and a mouse monoclonal
antibody directed against recombinant human heparanase, as
described previously.
(11,12,34,35)
Tumor biology
Four- to 6-week-old female SCID mice were purchased from
Harlan(Indianapolis,IN,USA)andallowedtoacclimatefor7days.
In the two experiments, animals (five or four per group) received
up to 2 10
6cells (HPSE-Low or HPSE-High) in each of four
different injection sites within the mammary fat pads (two
axillary and two abdominal), as described previously.
(12) All
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Arkansas for Medical Sciences (UAMS) IACUC-approved protocol.
Histology and osteoclast determination
Osteoclastswereidentifiedinmouselongbonesthatwereexcised,
fixedin10%neutral-bufferedformalinfor2days,anddecalcifiedin
5% formic acid with agitation until deemed clear by the
ammonium oxalate endpoint test.
(36) The decalcified specimens
then were dehydrated through graded ethanol and cleared in
methyl salicylate before paraffin infiltration. Subsequently, the
tissue was embedded in paraffin, sectioned (5mm), and stained
with hematoxylin and eosin (H&E) as described previously
(32,36,37)
and tartrate-resistant acid phosphatase (TRACP) using the Acid
Phosphatase Leukocyte Kit (Sigma) as described previously.
(32)
Osteoclasts were identified as TRACP
þ multinucleated cells
apposed to the bone surface, as described previously.
(33)
Isolation and culture of peripheral blood mononuclear
cells and their differentiation to osteoclasts
Peripheral blood was collected from healthy donors (approved
by the UAMS Institutional Review Board) using heparin as an
anticoagulant and 200ng/mL RANK-Fc to minimize any priming
of osteoclast progenitors by endogenous RANKL, as described
previously.
(32)
Blood was diluted in sterile PBS (1:1) in a sterile hood. The
blood-PBS solution was slowly layered over AccuPrep solution
(AccurateChemicals, Westbury, NY,USA) andthencentrifuged at
400g in swinging buckets for 30minutes at 218C. The peripheral
blood mononuclear cell (PBMC) layer was collected and washed
in five to six volumes of PBS, isolated by centrifugation at 140g,
and resuspended in a-MEM containing 10% FBS. Cells were
counted with a hemocytometer and plated in 48-well tissue
culture plates at a concentration of 0.5 million cells in 0.5mL
volume per well. Macrophage colony-stimulating factor (mCSF,
25ng/mL; R&D systems) was present in all treatment groups.
RANKL (25ng/mL; R&D systems) or IL-8 (10ng/mL) were used as
positive controls for the stimulation of osteoclastogenesis.
(32)
Conditioned medium from heparanase-high, heparanase-low,
M225, and M343 breast cancer cells growing in culture was
added to wells that received only mCSF. For these experiments,
medium was harvested 48 hours after cell plating, diluted 50%
with a-MEM, and added to the cultures of human PBMCs. All
conditioned-medium stimulation of osteoclastogenesis (and
bone resorption) occurred in the absence of exogenously added
RANKL or IL-8.
In addition, for some treatments, syndecan-1 was immunode-
pleted from conditioned medium using monoclonal antibody B-
B4 (CD 138, Serotec, Raleigh, NC) and protein-G sepharose beads
(GE Healthcare Bio-Sciences AB, Uppsala, Sweden). The levels of
shed syndecan-1 accumulated in the conditioned media were
assessed by ELISA using an Eli-pair kit from Diaclone (Cell
Sciences, Inc., Norwood, MA, USA). The standard curve was linear
between 8 and 256ng/mL, and all samples were diluted to
concentrations within that range, as described previously.
(29)
Mononuclear cell cultures were maintained at 378C, and half
the medium in each well was replaced with fresh medium three
times per week. The experiment was terminated on day 10.
Medium was aspirated, and the cells were fixed with 10%
formalin. TRACP staining was performed for quantitation of
TRACP
þ multinucleated cells. The number of osteoclasts present
in the entire well was determined by manually counting TRACP
þ
cells that contained three or more nuclei. The numerical average
of cell counts from four replicate wells per treatment was
determined, and the results were expressed as the number of
TRACP
þ multinucleated cells per well per treatment group, as
described previously.
(32)
PBMC-derived osteoclast cultures on dentine slices
Peripheral blood was collected from healthy donors, and PBMCs
were isolated as described earlier. Dentine (a kind gift from
Professor Tim Skerry, University of Sheffield, UK) was sliced into
0.5 0.5cm pieces. The slices were collected in H2O and
sonicatedtwicefor1minuteeachtoremoveparticledebris.They
were then rinsed in two changes of water in between sonication
and sterilized for at least 30minutes in 100% ethanol. All dentine
slices were stored in 100% ethanol until use. On the day of
culture, dentine slices were washed four times with PBS and
twice with a-MEM. Using sterile forceps, one slice was placed in
each well of a 48-well plate (containing 0.5mL of a-MEM), and
the plate was incubated at 378C for 30minutes. Equilibration
medium then was aspirated off, and PBMCs were added to the
wells at a concentration of 1.0 10
6 cells per well in 0.5mL
volume. Precursors were allowed to adhere to the slices for 4
hours at 378C. Appropriate amounts of treatment medium were
prepared, and 0.5mL was added to wells in a replicate 48-well
plate (lacking dentine slices) with 4 wells per treatment group.
mCSF (25ng/mL) was present in all treatment groups including
control. The positive controls for stimulation of osteoclastic bone
resorption was the addition of either RANKL (25ng/mL) or IL-8
(10ng/mL).
(32) Using sterile forceps, slices (with adherent cells)
weretransferred to the second 48-well plate, being careful not to
inverttheslices.Halfthemediumwasexchangedthreetimesper
week. Cells were allowed to grow on dentine slices for 10 to 12
days, after which time the cultures were terminated. Dentine
slices were fixed in 10% formalin and stained for TRACP. The
dentine slices then were mounted on glass slides and examined
under a microscope. TRACP
þ multinucleated cells showing the
ability to resorb bone were counted as osteoclasts. Bone-
resorptionareawasmeasuredusinghistomorphometry software
(Osteomeasure, Atlanta, GA, USA) after removal of the cells by
sonication, as described previously.
(32)
Statistical analysis
Statistical significance between groups was determined by
analysis of variance (ANOVA) prior to post hoc pair-wise multiple
comparisons using the Student-Newman-Keuls method (Sigma-
Stat, Aspire Software International, Ashburn, VA, USA); p<.05
was considered significant.
Results
Breast cancer frequently metastasizes to bone via a process that
is apparently facilitated by increased bone turnover.
(6,38) In a
previous study we demonstrated that primary breast tumor
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expressing high levels of heparanase stimulated bone resorption
with no evidence of any detectable tumor cells within the
bone.
(12) This study was performed to determine the mechanism
for the distal osteolysis mediated by the heparanase-expressing
tumor cells.
Osteotropic MDA-MET breast cancer cells
(3) were engineered
to express high levels of wild-type heparanase (HPSE-High) or
transfected with the empty vector (HPSE-Low).
(12) In addition,
MDA-MET cells expressing catalytically inactive heparanases
designated M225 [mutated proton donor site of the active site
(Glu225 to Ala225)] and M343 [mutated nucleophilic residue of
the active site (Glu343 to Ala343)] were prepared. Analysis by
Western blot and heparanase activity assays confirmed that cells
overexpressing wild-type heparanase had high levels of
heparanase protein and high levels of heparan sulfate degrading
activity, whereas cells expressing mutant heparanases had high
levels of heparanase protein that was catalytically inactive and
did not degrade heparan sulfate
(29) (Fig. 1).
Medium conditioned by HPSE-High cells enhanced osteoclas-
togenesis in vitro compared with medium conditioned by HPSE-
Lowcells,confirmingourpriorobservations
(12)(Fig.2).Moreover,
pretreatment of the conditioned medium with heparinase III
(HepIII), a bacterial enzyme that extensively degrades heparan
sulfate, completely abolished the enhanced osteoclastogenic
activity of medium from HPSE-High cells (Fig. 2). This
demonstrates that the enhanced osteoclastogenic activity of
HPSE-High cells requires intact heparan sulfate. However, boiling
the conditioned medium greatly reduced the osteoclastogenic
activity of all samples regardless of the presence or absence of
HepIII, demonstrating the importance of other protein factors in
the conditioned medium (Fig. 2). Together these results suggest
that the enhanced osteoclastogenic effect in the conditioned
medium from HPSE-High cells requires both intact heparan
sulfate chains and heat-labile factors.
Fig. 1. Heparanase protein levels and enzyme activity. The graph shows
the heparan sulfate–degrading activity of the reaction buffer (Buffer),
recombinant enzymatically active human heparanase (rHPSE, 1mg), and
cell extracts of HPSE-Low cells, HPSE-High cells, and cells expressing
enzymatically inactive heparanase (M225 and M343). (Inset) Western
blots of cell extracts probed with antibody to human heparanase. At
the exposure shown, the most prominent band is the 50-kDa fully
processed form of the enzyme in HPSE-High cells (High) and the two
mutants (M225 and M343). Each lane was equivalently loaded for protein
(30mg).
Fig. 2. Conditioned medium from HPSE-High cells stimulates osteoclastogenesis. An in vitro osteoclastogenesis assay was used to evaluate conditioned
medium from HPSE-Low (left side) and HPSE-High cells (right side), as indicated below the bars (HPSE). Other treatments of the medium prior to
osteoclastogenesis (HepIII or boiled) are also indicated below the bars. Medium from HPSE-Low cells, as well as treatment with RANKL or IL-8, produced
significant osteoclastogenesis compared with csf-1-only control (p<.05 indicated by single asterisk). Medium from HPSE-High cells was significantly
higher than that of HPSE-Low cells (p<.05 indicated by double asterisk). HepIII-treated conditioned medium from HPSE-High cells reduced osteoclast
formation to the extent that it was not significantly different from the osteoclastogenic activity of the conditioned medium from the HPSE-Low cells but
wasstillhigherthancsf-1control.BoilingtheconditionedmediumorboilingafterHepIIItreatmentcompletelyabolishedtheosteoclastogenesisactivityof
the conditioned medium from either the HPSE-High or HPSE-Low cells down to csf-1 control levels. Results are indicative of at least three replicate
experiments.
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slices to measure the bone-resorbing activity of osteoclasts
induced by medium from HPSE-High or HPSE-Low tumor cells.
Consistent with the findings in Fig. 2, significantly more
osteoclasts formed in response to medium from HPSE-High
cells than medium from HPSE-Low cells (not shown), and the
totalareaofbone resorbed by those osteoclasts was significantly
greater than that in bone exposed to medium from HPSE-Low
cells (p<.05; Fig. 3). However, osteoclasts generated in the
presence of medium from HPSE-High cells created individual
resorption pits that were not significantly different in area or
depth from the pits formed by osteoclasts from HPSE-Low cells.
In fact, the mean area of bone resorbed per osteoclast was
0.0036 0.00067mm
2 for osteoclasts formed by medium from
HPSE-high cells and 0.0032 0.00053mm
2 for osteoclasts
formed by medium from HPSE-Low cells, and these were not
statistically different (p>.05). Similarly, no differences were
observed in the number of nuclei per osteoclast in either HPSE-
High or HPSE-Low conditioned-medium cultures (data not
shown). Thus the enhanced bone resorption observed with the
heparanase-expressing tumor cells is due to their impact on
osteoclastogenesis (ie, increased osteoclast numbers) and not an
effect of any increase in the activity or size of the individual
osteoclasts.
Based on the results in Figs. 2 and 3, we hypothesized that the
distal osteolysis induced by tumors in the mammary fat pad of
mice
(12) was due to increased osteoclast numbers in the long
bones of mice bearing HPSE-High tumors compared with those
from animals bearing HPSE-Low tumors. To test this, histomor-
phometric analysis of the long bones from tumor-bearing mice
was performed. The results confirmed that significantly more
osteoclasts per millimeter of bone surface were present in
animals bearing tumors formed by HPSE-High cells compared
with those bearing tumors formed by HPSE-Low cells (p<.05;
Fig. 4). The animals with HPSE-High tumors also had increased
serum levels of TRAP-5b and collagen telopeptides relative to
levels of these markers in the sera of mice bearing tumors of
HPSE-Low cells.
(12) These data demonstrate that the increased
osteoclast numberobserved inHPSE-High tumor-bearing miceis
reflected in the increased serum biochemical markers of bone
resorption.
Because enzymatically inactive heparanase also may exert
effects on cell behavior.
(9) the osteoclastogenic activity of
medium conditioned by cells expressing enzymatically inactive
heparanase was examined. The results demonstrated that
medium conditioned by cells expressing enzymatically inactive
heparanase does not enhance osteoclastogenesis beyond the
level seen in medium from the HPSE-Low cells (Fig. 5).
In contrast to HepIII, which significantly degrades heparan
sulfate into non–biologically active fragments, human hepar-
anase cleaves heparan sulfate into biologically active fragments
of 5 to 7kDa.
(9) In addition, heparanase also enhances the
expression and shedding of syndecan-1 from the cell surface.
(29)
To determine whether heparan sulfate fragments or intact
syndecan-1 were responsible for the increased osteoclastogen-
esis, syndecan-1 was immunoprecipitated from conditioned
medium using the B-B4 antibody that recognizes the core
protein of syndecan-1 (CD 138, Serotec, Raleigh, NC). This
treatment removes all syndecan-1 from the medium to a level
that is below the limit of detection of the syndecan-1 ELISA
( 17ng/mL). In contrast, HPSE-High conditioned medium
Fig. 3. Medium from HPSE-High cells enhances bone resorption. Quan-
tification of bone resorption on bone slices. Human osteoclasts were
differentiated from PBMCs grown on bone and exposed to cell culture
medium that was not conditioned by breast cancer cells (Control) or
medium with addition of RANKL (RANKL), IL-8 (IL-8), or medium condi-
tioned by HPSE-High cells (HPSE-High), and medium conditioned by
HPSE-Low cells (HPSE-Low). The $ indicates that all treatments are
significantly different from csf-1 control (p<0.05). The asterisk indicates
that HPSE-High conditioned medium produced significantly more bone
resorption than the all other conditions with p<.05. Results are indica-
tive of at least two replicate experiments.
Fig. 4. Orthotopic HPSE-High breast tumors increase osteoclast numbers in long bones. Femurs from animals bearing mammary fat pad tumors formed
by HPSE-High or HPSE-Low cells were stained for TRACP, and the numbers of TRACP
þ multinucleated cells were determined (A, experiment 1, n¼5
animalspergroup;B,experiment2,n¼4animalspergroup).Aminimumofthreesectionsofboneperanimalwerecounted.Errorbarsrepresentstandard
error, and statistical significance was determined by a two-tailed t test. Significance was identified by p<.05.
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beads coated with non-immune IgG.
The absence of syndecan-1 significantly diminished the
enhanced osteoclastogenic activity of medium conditioned by
HPSE-High cells (Fig. 6A). Immunodepletion and subsequent
HepIII treatment further reduced the extent of osteoclastogen-
esis induced by the conditioned medium to the levels observed
for HPSE-Low cells (Fig. 6B). Interestingly, the reduction in
osteoclastogenic activity owing to HepIII treatment and
syndecan-1 depletion was not significantly different from the
osteoclastogenic activity of immunodepleted syndecan-1 alone.
Collectively, these data demonstrate that shed syndecan-1, and
not the heparanase-generated fragments of heparan sulfate, is
critical for the enhanced osteoclastogenic activity of the tumors
formed by the HPSE-High cells.
Elevated levels of the alpha chemokine IL-8 are associated
with the increased bone metastasis and osteolysis of human
breast cancer cells.
(3,32,33) IL-8 is a heparan sulfate–binding
osteoclastogenic factor and as such could cooperate with the
heparansulfatechainsonthesyndecan-1shedbytheHPSE-High
cells. IL-8 is released into the medium by both HPSE-Low and
HPSE-High cells. HPSE-High cells secrete 78 2ng/mg of IL-8
protein into conditioned medium compared with 32 2ng/mg
secreted by HPSE-Low cells into the conditioned medium.
Interestingly, IL-8 levels are also elevated in the sera of mice
bearing tumors of HPSE-High cells (15 2ng/mL) compared
with IL-8 levels in the sera of mice bearing HPSE-Low tumors
(3 1ng/mL).
We and others have shown that IL-8 is a potent osteoclasto-
genic agent. Indeed, only 10ng/mL of IL-8 is sufficient to
stimulate osteoclastogenesis ininvitropreparationsofPBMCs
(33)
(Fig. 7). A function-blocking antibody to IL-8 can completely
abrogate the osteoclastogenesis mediated by recombinant
human IL-8
(33) (Fig. 7A, B; compare IL-8– to IL-8þ). This IL-8
antibody also significantly suppresses the enhanced osteoclas-
togenic activity of the HPSE-High cells, demonstrating that IL-8 is
an osteoclastogenic component of the conditioned medium
(Fig. 7A). As expected, the same IL-8 antibody almost completely
abrogated the osteoclastogenesis promoted by medium con-
ditioned by HPSE-Low cells (Fig. 7A), demonstrating that IL-8 is
the principal component of the osteoclastogenic activity in the
mediumfromthesecells.Weinvestigatedthecombinedeffectof
blockade of IL-8 and immunodepletion of syndecan-1 and found
that the suppression of osteclastogenesis was greatly enhanced
over either treatment alone (Fig. 7B).
Discussion
This study addresses the mechanism(s) whereby expression of
heparanase by tumor cells enhances systemic osteolysis. Using
histomorphometric analysis of bones from an animal model of
breast cancer and in vitro assays of osteoclastogenesis and bone
resorption, we discovered that (1) mammary fat pad tumors
expressing high levels of heparanase stimulate osteoclastogen-
esis in distant bones, (2) medium from cells expressing high
levels of heparanase stimulates osteoclastogenesis in vitro and
bone resorption at levels significantly above those of medium
from cells expressing low levels of heparanase, and (3) the
enhanced osteoclastogenesis requires the presence of synde-
Fig. 5. Enzymatically active heparanase is required for stimulation of osteoclastogenesis. Media conditioned by cells expressing enzymatically active or
inactive heparanase were tested for the capacity to stimulate osteoclastogenesis in vitro. Medium from HPSE-Low cells induced osteoclastogenesis that
was significantly greater than csf-1 control (
 p<.05) and not different from M225, and M343 cells expressing inactive heparanases. The osteoclastogenic
activity of HPSE-High cells was significantly greater than the other heparanase-expressing cells ($, p<.05). As a positive control, osteoclastogenesis
induced following the addition of RANKL or IL-8 is also significantly different from control (
 p<.05). Results are indicative of at least three replicate
experiments.
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isenhancedbythe expressionofheparanase andproteinagents,
such as IL-8. In addition, these effects depend on the expression
of the enzymatically active form of heparanase, suggesting that
they occur downstream of the heparanase degradation of
heparan sulfate. These results reveal a novel mechanism
whereby expression of heparanase by tumor cells upregulates
the shedding of syndecan-1, which after entering the systemic
circulation stimulates osteoclastogenesis and enhances bone
destruction.
The finding that syndecan-1 shed by breast cancer cells
participates in driving osteolysis adds to the growing list of
important functions of this proteoglycan within the tumor
microenvironment. For example, the expression of syndecan-1
by stromal cells and its shedding have been linked to
proliferation and angiogenesis of breast cancer cells, which is
at least in part due to enhanced fibroblast growth factor 2 (FGF-
2) signaling.
(30,39) Increased shedding of syndecan-1 also has
beenassociatedwithincreasedMCF-7breastcancercellinvasion
through matrigel, suggesting a role for shed syndecan-1 in the
invasive phenotype of tumor cells.
(40) Interestingly, shed
syndecan-1 also promotes the growth, metastasis, and angio-
genesis observed in multiple myeloma,
(41) another cancer with
an aggressive osteolytic phenotype.
Although our results demonstrate that the heparan sulfate
chains of syndecan-1 are required for its effect in stimulating
osteoclastogenesis, we cannot rule out the possibility that the
core protein of syndecan-1 is also involved. This is particularly
important inlightofrecent studiesshowingthatthecore protein
of syndecan-1, even when added exogenously to cells, can
activate aVb3 and aVb5 integrins.
(24,25,42) Importantly, the aVb3
integrin is expressed on the surfaces of osteoclasts,
(43) and
inhibitors of this integrin can block metastasis to bone and
tumor-related osteolysis.
(44,45) Thus it is compelling to speculate
that the shed syndecan-1 activates the aVb3 integrin on
osteoclasts, thereby enhancing osteoclastogenesis.
The impact of shed syndecan-1 on osteoclastogenesis is
important because it provides a novel mechanism for the
extensive osteolysis seen in many breast cancer patients. Bone
metastases frequently are associated with the later stages of
disease progression and relapse and may not be evident when
the cancer is first diagnosed,
(46) suggesting that the initial stages
of bone metastasis may not be completed when patients are
initially diagnosed.
Fig. 6. Shed syndecan-1 in conditioned medium of HPSE-High cells is required for enhanced osteoclastogenesis. (A) Osteoclastogenesis was increased
significantly compared with control (csf-1 alone) in media conditioned by cells expressing low or high heparanase, as well as by the addition of IL-8 or
RANKL (p<.05). Moreover, as expected, osteoclastogenesis was significantly higher for HPSE-high conditioned medium than for HPSE-low medium
(
 p<.05). However, only osteoclastogenesis stimulated by conditioned medium from cells expressing high levels of heparanase was decreased
significantlybyimmunoprecipitationwithaspecificantibodytosyndecan-1(Syn-1,$)butnotbyimmunoprecipitationwithIgG.Resultsareindicativeofat
least three replicate experiments. (B) Immunoprecipitation of syndecan-1 from medium conditioned by heparanase-high cells significantly reduced the
number of osteoclasts compared with medium without immunoprecipitation (
  p<.05). Similalrly, immunoprecipitation of syndecan-1 from medium
followed by HepIII treatment of medium also reduced the number of osteoclasts significantly compared with HPSE-High conditioned medium alone
(
  p<.05). HepIII treatment did not significantly reduce osteoclastogenesis compared with medium that lacked syndecan-1. Results are indicative of at
least two replicate experiments.
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earliest stages of the formation of bone metastases
(47,48) and is
clearly involved in the initial colonization of bone by migrating
breast cancer cells.
(7) Once resorption is activated, disseminated
tumor cells relocate to the bone marrow microenvironment and
eventually the bone itself. As the metastatic foci grow,
heterogeneity again may develop, potentially including cells
with different metastatic capabilities and potential.
(5)
Heparanase is upregulated in many tumor types and has been
associated with increased metastasis and poor prognosis in
breast cancer.
(10) It hasbeen suggested that much of heparanase
function is regulated by its remodeling of the extracellular matrix
and by its effects on cell signaling.
(49) Our findings provide new
insight into how heparanase regulates tumor behavior via
upregulation of syndecan-1 shedding. Interestingly, enhanced
syndecan-1 sheddingdependsontheheparansulfate degrading
activity of heparanase,
(29) consistent with our finding that
heparanase enzymatic activity is required for the enhanced
osteoclastogenic effect of the heparanase-high breast cancer
cells.
Overall, these results suggest a model where heparanase
upregulation bytumorcellsdegradesheparansulfate chainsand
enhances syndecan-1 shedding. The shed and active syndecan-1
is free to diffuse within the tumor microenvironment or to enter
the circulation and travel to distal tissues, where it affects the
behavior of host cells, such as osteoclasts and their precursors. It
is also possible that the distal effects on osteoclasts we have
observed helps to prepare premetastatic niches that are
receptive to incoming circulating tumor cells. Further investiga-
tion ofthe roleof theheparanase–shed syndecan-1 axis inbreast
cancer progression should focus on disruption of heparanase
function, which is likely to profoundly affect tumor growth,
metastasis, and osteolysis.
Immunodepletion of syndecan-1 from the medium is
sufficient to reduce osteoclastogenesis to control levels,
suggesting that syndecan-1 is the specific heparan sulfate
proteoglycan that stimulates the enhancement of osteoclasto-
genesis by HPSE-High cells. In addition, the background (and
substantial) osteoclastogenic activity of conditioned medium
from HPSE-Low cells (and heparanase mutant cells) is pre-
sumablyduetotheexpressionoftheosteolyticcytokineIL-8that
is still expressed by these cells.
(33) Although syndecan-1 on the
surfaces of myeloma cells can bind to osteoprotegerin (OPG),
leading to its internalization and degradation,
(50) we do not
believe that this inhibits IL-8-mediated osteoclastogenesis
because we have shown previously that the addition of OPG
(or RANK-Fc) did not inhibit IL-8-induced osteoclastogenesis
in vitro.
(32,33) Moreover, in our in vivo model where we see
enhanced osteoclastogenesis, the tumor cells are not present
in the bone and thus are not likely altering local OPG levels in
the bone. However, we cannot rule out the possibility that the
clearance of OPG from the circulation by tumors distal to the
Fig. 7. IL-8 is a heparan sulfate–binding cytokine that cooperates with shed syndecan-1 to promote osteoclastogenesis. (A) Addition of IL-8 or RANKL
significantly increases osteoclast formation compared with csf-1 control, as does medium from HPSE-High or -Low cells ($, p<.05). Treatment with a
neutralizing IL-8 antibody significantly decreased osteoclast formation in all groups (
  ) except RANKL. Treatment of heparanase-low cells with IL-8
antibody was significantly different from all other conditioned media groups (
  p<.05). Conditioned medium from HPSE-High cells treated with IL-8
antibody retained significantly higher osteoclastogenesis than csf-1 control ($, p<.05). Addition of the IL-8 antibody significantly reduced the
osteoclastogenesis relative to untreated HPSE-High conditioned medium (
  p<.05); therefore, this data point is marked ($
  ). (B) Addition of IL-8
significantly increased osteoclast formation compared with csf-1 control ($, p<.05). The increased osteoclastogenesis was completely abolished by
addition of the IL-8 function-blocking monoclonal antibody. Blocking IL-8 and depleting syndecan-1 dramatically reduced the osteoclastogenesis of both
HPSE-Low and HPSE-High conditioned medium. The osteoclastogenic activity of HPSE-High conditioned medium was decreased significantly by IL-8
blockade and syndecan-1 depletion relative the IL-8-positive control (
  ) but remained significantly different from csf-1 control ($
  ). Results are indicative
of at least two replicate experiments.
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osteoclastogenesis in our animal model.
Collectively, these data demonstrate that shed syndecan-1 in
the conditioned medium is not the sole agent stimulating
osteoclastogenesis. Although syndecan-1 is the primary heparan
sulfate proteoglycan stimulating osteoclastogenesis in the
conditioned medium, boiling also abrogated osteoclastogenic
activity. Heparan sulfate is impervious to boiling; however,
proteins are not. This suggests that syndecan-1 acts in concert
with other heparin-binding growth factors to stimulate the
potent osteoclast formation observed. As mentioned earlier, an
attractive candidate for this activity is IL-8. IL-8 is a CXC-
chemokine that is activated by interaction with heparan
sulfate
(51) and that has been shown to directly stimulate
osteoclast formation and activity.
(32) Importantly, the hepar-
anase-high cells were derived from the osteolytic IL-8 expressing
MDA-MET human breast cancer cells.
(3,12) As such, the
heparanase-high (and heparanase-low) cells also produce
significant and measurable levels of human IL-8 (HPSE-High:
78 2ng/mg of protein; HPSE-Low: 32 5ng/mg of protein). In
addition, other heparin-binding growth factors may contribute
to enhancing osteoclastogenesis or to creating an osteoclasto-
genic environment (e.g., FGFs, insulin-like growth factor–binding
proteins, and platelet-derived growth factor). Binding of heparan
sulfate of syndecan-1 to these factors can promote their
interaction with high-affinity receptors on the cell surface
and/or protect the factors from proteolytic degradation within
the bone microenvironment. In addition, a region of the
syndecan-1 core protein has been shown to activate aVb3
integrin on cell surfaces.
(25) Because activation of aVb3 integrin
on osteoclasts is critical for normal osteoclast function and bone
resorption,
(52) syndecan-1 also could be playing a role in
stimulating osteoclastogenesis in vivo via the activity of its core
protein interacting with osteoclast surface integrins.
Interestingly, after implantation in the mammary fat pad,
serum IL-8 levels are measurable only in animals bearing HPSE-
High tumors, suggesting a role for HPSE in the access of tumor-
derived cytokines to the circulation (HPSE-High: 15 2ng/mL;
HPSE-Low: 3 1ng/mL (at the detection limit of the assay).
Understanding of the combined effects of heparanase, synde-
can-1, and IL-8 on breast cancer progression, development of
bone metastases, and activation of bone resorption is currently
thefocus ofintenseinvestigation inourlaboratory. Whatever the
case, it is clear that the osteolytic phenotype of aggressive
human breast cancer cells involves multiple factors, including,
but not limited to, heparanase, syndecan-1, and IL-8.
The finding that syndecan-1 shed from the surface of tumor
cells is another important mediator of osteoclastogenesis
identifies the heparanase–syndecan-1–cytokine axis as a novel
target for inhibiting osteoclastogenesis and ultimately for
preventing the consequences of bone metastases. We and
others have speculated that heparanase acts as a master
regulator of the aggressive tumor phenotype
(29) that is likely the
result of heparanase effects on multiple cell behaviors, including
the regulation of tumor osteolysis. Further investigation of the
role of this important axis in breast cancer progression should
focus on disruption of heparanase function, which is likely to
profoundly affect tumor growth, metastasis, and osteolysis.
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